Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C.
Humans
Hepatitis C, Chronic
/ drug therapy
Male
Female
Antiviral Agents
/ therapeutic use
Interferons
Polymorphism, Single Nucleotide
Middle Aged
Interleukins
/ genetics
Adult
Egypt
Forkhead Transcription Factors
/ genetics
Treatment Outcome
Promoter Regions, Genetic
Immunogenetics
Interferon Lambda
DAA
Daclatasvir
FOXP3
HCV
IL28B
Sofosbuvir
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
received:
10
04
2024
accepted:
09
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
8
8
2024
Statut:
epublish
Résumé
The prevalence of HCV infection in Egypt has decreased following the introduction of direct-acting antiviral therapy. However, treatment response is influenced by various factors, particularly host immunogenetics such as IL-28B and FOXP3 polymorphisms. The current study examined the impact of SNPs in the FOXP3 gene promoter region on HCV-infected Egyptian patients, along with SNPs in the IL28B gene.This study involved 99 HCV patients who achieved SVR12 after a 12 week DAA treatment while 63 HCV patients experienced treatment failure. IL28B rs12979860 SNP was identified using real-time PCR, while IL28B rs8099917, FOXP3 rs3761548, and rs2232365 SNPs were analyzed using RFLP-PCR. Serum levels of IL28B and FOXP3 were quantified using ELISA technique in representative samples from both groups. The IL28B rs12979860 T > C (P = 0.013) and FOXP3 rs2232365 A > G polymorphisms (P = 0.008) were found to significantly increase the risk of non-response. Responders had higher IL28B serum levels (P = 0.046) and lower FOXP3 levels (P < 0.001) compared to non-responders. Regression analysis showed an association between IL28B rs12979860 and FOXP3 rs2232365 with treatment response, independent of age and gender. A predictive model was developed with 76.2% sensitivity and 91.9% specificity for estimating DAAs response in HCV patients.Our findings confirmed the IL28B rs12979860 T > C and FOXP3 rs2232365 A > G polymorphisms significantly affect DAA treatment response in HCV Egyptian patients. Lower levels of IL-28B along with higher levels of FOXP3 are linked to poor response. Our results may lead to new insights into DAA responsiveness contributing to personalized medicine and improving therapeutic decision-making for HCV patients.
Identifiants
pubmed: 39117877
doi: 10.1007/s10238-024-01432-x
pii: 10.1007/s10238-024-01432-x
doi:
Substances chimiques
Antiviral Agents
0
Interferons
9008-11-1
interferon-lambda, human
0
Interleukins
0
FOXP3 protein, human
0
Forkhead Transcription Factors
0
Interferon Lambda
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
184Informations de copyright
© 2024. The Author(s).
Références
World Health Organization: WHO [Internet]. 2023 [cited 2023 Aug 28]. Hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Manns MP, Maasoumy B, Rice CM. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022;19:533–50.
pubmed: 35595834
pmcid: 9122245
doi: 10.1038/s41575-022-00608-8
Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–91.
pubmed: 10752705
doi: 10.1016/S0140-6736(99)06527-7
Esmat G, El-Sayed MH, Hassany M, Doss W, Waked I. One step closer to elimination of hepatitis C in Egypt. Vol. 3, The Lancet Gastroenterology and Hepatology. Elsevier Ltd; 2018. p. 665.
Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553–62.
pubmed: 23817321
doi: 10.1038/nrgastro.2013.107
Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis. 2018;218(11):1722–9.
pubmed: 29982508
doi: 10.1093/infdis/jiy401
Wantuck JM, Ahmed A, Nguyen MH. Review article: The epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther. 2014;39(2):137–47.
pubmed: 24251930
doi: 10.1111/apt.12551
Abdel-Samiee M, Youssef MI, Elghamry F, Bazeed M, Al-Shorbagy M, Shalaby H, et al. A multicentric and nationwide predictive study role of T cell sub-population in the prevalence and prognosis of cryoglobulinemia among genotype 4 chronic hepatitis C patients. J Med Virol. 2023;95(12):e29248.
pubmed: 38108641
doi: 10.1002/jmv.29248
Götte M, Feld JJ. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol. 2016;13(6):338–51. https://doi.org/10.1038/nrgastro.2016.60 .
doi: 10.1038/nrgastro.2016.60
pubmed: 27147491
Abozeid M, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, et al. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2018;75:109–14.
Liver EA for the S of the. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). Vol. 73, Journal of hepatology. Netherlands; 2020. p. 1170–218.
Hoofnagle JH, Sherker AH. Therapy for hepatitis C — The costs of success. N Engl J Med. 2014;370(16):1552–3.
pubmed: 24725236
doi: 10.1056/NEJMe1401508
Essa M, Sabry A, Abdelsameea E, Tharwa ES, Salama M. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. Eur J Gastroenterol Hepatol. 2019;31(1):53–8.
pubmed: 30247174
doi: 10.1097/MEG.0000000000001250
Schwander B, Feldstein J, Sulo S, Gonzalez L. Pursuing elimination of hepatitis C in Egypt : cost- effectiveness and economic evaluation of a country- wide program. Infect Dis Ther. 2022;11(3):1193–203. https://doi.org/10.1007/s40121-022-00631-x .
doi: 10.1007/s40121-022-00631-x
pubmed: 35451742
pmcid: 9124269
Nahon P, Cobat A. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet. 2020;139(6–7):855–63. https://doi.org/10.1007/s00439-020-02136-4 .
doi: 10.1007/s00439-020-02136-4
pubmed: 32100095
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.
pubmed: 19749758
doi: 10.1038/ng.447
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
pubmed: 19684573
doi: 10.1038/nature08309
America N, Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. Genome-wide association of IL28B with response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.
doi: 10.1038/ng.449
Khan AJ, Saraswat VA, Ranjan P, Parmar D, Negi TS, Mohindra S. Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. J Med Virol. 2019;91(4):659–67. https://doi.org/10.1002/jmv.25359 .
doi: 10.1002/jmv.25359
pubmed: 30431653
El-Garawani I, Hassab El-Nabi S, Gadallah M, Abdelsameea E. Association between IFN-λ 3 gene polymorphisms and outcome of treatment with direct acting antivirals in chronic HCV-infected Egyptian psatients. Immunol Invest. 2020;50(1):1–11. https://doi.org/10.1080/08820139.2020.1722158 .
doi: 10.1080/08820139.2020.1722158
Ghanem SE, Elsabaawy M, shebl N, Abdelsameea E, Othman W, EL-Bassal FI, et al. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Expert Rev Anti Infect Ther. 2020;18(9):947–54.
pubmed: 32419526
doi: 10.1080/14787210.2020.1771180
Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.
pubmed: 12483210
doi: 10.1038/ni875
Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–8.
pubmed: 12469119
doi: 10.1038/ni873
Wack A, Terczyn E, Hartmann R. Guarding the frontiers : the biology of type III interferons. Nat Immunol. 2015;16(8):802–9.
pubmed: 26194286
pmcid: 7096991
doi: 10.1038/ni.3212
Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, et al. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res. 2015;2015:768470.
pubmed: 25811035
pmcid: 4355603
doi: 10.1155/2015/768470
Moghimi M, Tavakoli F, Doosti M, Ahmadi-Vasmehjani A, Akhondi-Meybodi M. Correlation between interleukin-28 gene polymorphism with interleukin-28 cytokine levels and viral genotypes among HCV patients in Yazd. Iran BMC Res Notes. 2019;12(1):10–4. https://doi.org/10.1186/s13104-019-4651-z .
doi: 10.1186/s13104-019-4651-z
Oda JMM, Hirata BKB, Guembarovski RL, Watanabe MAE. Genetic polymorphism in FOXP3 gene: Imbalance in regulatory T-cell role and development of human diseases. J Genet. 2013;92(1):163–71.
pubmed: 23640423
doi: 10.1007/s12041-013-0213-7
Wu KJ, Qian QF, Zhou JR, Sun DL, Duan YF, Zhu X, Lu YJ. Regulatory T cells (Tregs) in liver fibrosis. Cell death discovery. 2023;9(1):53.
pubmed: 36759593
pmcid: 9911787
doi: 10.1038/s41420-023-01347-8
Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005;6:353–60.
pubmed: 15785761
doi: 10.1038/ni1181
Zhao H, Liao X, Kang Y. Tregs: Where we are and what comes next? Front Immunol. 2017;8:1578.
pubmed: 29225597
pmcid: 5705554
doi: 10.3389/fimmu.2017.01578
Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR, et al. Functional analysis of human promoter polymorphisms. Hum Mol Genet. 2003;12(18):2249–54.
pubmed: 12915441
doi: 10.1093/hmg/ddg246
Kao HH, Yu RL, Chuang WL, Huang JF, Dai CY, Tan CH. Genetic polymorphisms of regulatory T cell-related genes modulate systemic inflammation induced by viral hepatitis. Kaohsiung J Med Sci. 2021;37(11):1000–9.
pubmed: 34166564
doi: 10.1002/kjm2.12414
Pereira LMS, da Amoras E, SG, Conde SRS d. S, Demachki S, Monteiro JC, Martins-Feitosa RN, et al. The -3279C > A and -924A > G polymorphisms in the FOXP3 gene are associated with viral load and liver enzyme levels in patients with chronic viral liver diseases. Front Immunol. 2018;9:1–16.
doi: 10.3389/fimmu.2018.02014
Weng CL, Yazid H, Appalasamy S, Geng BJ, Nasir WMNWM, Muhammad NMN, et al. Optimization of binding washing and elution buffer for development of DNA isolation kit. IOP Conf Ser Earth Environ Sci. 2020;596(1):012008.
doi: 10.1088/1755-1315/596/1/012008
Zakaria ZA, Knapp S, Hashem M, Zaghla H, Thursz M, Waked I, et al. Interleukin 28A rs12980602 and interleukin 28B rs8103142 genotypes could be protective against HCV infection among Egyptians. Immunol Res. 2019;67(1):123–33.
pubmed: 30402710
doi: 10.1007/s12026-018-9035-2
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5.
pubmed: 15297300
doi: 10.1093/bioinformatics/bth457
Flower B, Nguyen Thi Ngoc P, McCabe L, Le Ngoc C, Vo Thi T, Thi Kim HV, et al. Rise in alanine aminotransferase after HCV treatment is a highly sensitive screen for treatment failure. Clin Liver Dis. 2023;21(5):138–42.
doi: 10.1097/CLD.0000000000000055
Ayoub HH, Mahmud S, Chemaitelly H, Abu-Raddad LJ. Treatment as prevention for hepatitis C virus in the middle East and North Africa: a modeling study. Front Public Heal. 2023;11:1–13.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, Ohuigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.
pubmed: 19759533
pmcid: 3172006
doi: 10.1038/nature08463
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9. https://doi.org/10.1038/ng.449 .
doi: 10.1038/ng.449
pubmed: 19749757
Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–9.
pubmed: 20399780
doi: 10.1053/j.gastro.2010.04.013
Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53(3):439–43. https://doi.org/10.1016/j.jhep.2010.03.022 .
doi: 10.1016/j.jhep.2010.03.022
pubmed: 20576307
Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52(1):33–7.
pubmed: 20578254
doi: 10.1002/hep.23624
Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139(3):821–7.
pubmed: 20621700
doi: 10.1053/j.gastro.2010.05.079
Salum GM, Dawood RM, Abdel-Meguid M, Ibrahim NE, Aziz AOA, Awady MKEl. Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. Genes Dis. 2020;7(3):392–400.
pubmed: 32884993
doi: 10.1016/j.gendis.2019.05.004
Sghaier I, Mouelhi L, Gazouani E, Morel V, Besma YL, Brochot E. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population. J Clin Virol. 2015;69:184–9.
pubmed: 26209404
doi: 10.1016/j.jcv.2015.06.102
Stättermayer AF, Ferenci P. Effect of IL28B genotype on hepatitis B and C virus infection. Curr Opin Virol. 2015;1(14):50–5.
doi: 10.1016/j.coviro.2015.07.011
Zaki SM, Ahmed HS, Yousif MM, Awad EM. Interleukin 28B polymorphism as a predictor of sustained virological response to sofosbuvir-based therapy for hepatitis C virus patients. Trop Med Infect Dis. 2022;7(9):230.
pubmed: 36136642
pmcid: 9501239
doi: 10.3390/tropicalmed7090230
El- KSH, El- SM, Zakarya ZM, Helal GK. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. J Clin Pharm Ther. 2021;46:942–9.
doi: 10.1111/jcpt.13417
Zidan HE, Talaat RM, Ammar AAA, Sakr MA. Interleukin 28B polymorphism as a predictor of response to treatment of Egyptian HCV patients working in nuclear material authority. Egypt J Hosp Med. 2019;77(1):4742–7.
doi: 10.21608/ejhm.2019.46755
Kuralay Z, Tuğ E, Fidan I. Investigation of the relationship between IL28B polymorphisms and plasma IL28B levels in patients with chronic hepatitis B or C. Mikrobiyol Bul. 2021;55(3):374–88.
doi: 10.5578/mb.20219807
Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, et al. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int. 2014;34(6):890–5.
pubmed: 24102823
doi: 10.1111/liv.12321
Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med. 2013;158(4):235–45.
pubmed: 23420232
pmcid: 3638215
doi: 10.7326/0003-4819-158-4-201302190-00003
El-Fattah MA. Predictive power of Interleukin–28B gene variants for outcome of Hepatitis C virus genotype 4 in Egyptians: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021;45(2):101480. https://doi.org/10.1016/j.clinre.2020.06.006 .
doi: 10.1016/j.clinre.2020.06.006
pubmed: 32622719
Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load. J Med Virol. 2006;78(1):83–90.
pubmed: 16299715
doi: 10.1002/jmv.20507
Chadha N, Turner A, Sterling RK. Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR. J Viral Hepat. 2023;30(1):73–8.
pubmed: 36301045
doi: 10.1111/jvh.13763
Pachiadakis I, Pollara G, Chain BM, Naoumov NV. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infectious Diseases. 2005;5:296–304.
pubmed: 15854885
doi: 10.1016/S1473-3099(05)70114-6
Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119(7):1745–54.
pubmed: 19587449
pmcid: 2701885
doi: 10.1172/JCI39133
Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood. 2004;103(3):1026–9.
pubmed: 14525790
doi: 10.1182/blood-2003-04-1339
Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011;54(5):859–65. https://doi.org/10.1016/j.jhep.2010.08.020 .
doi: 10.1016/j.jhep.2010.08.020
pubmed: 21145813
Nasab SDM, Vasmehjani AA, Kaghazian H, Mardani R, Zali F, Ahmadi N, et al. Association of IL28B (IFNL3) rs12979860 mRNA levels, viral load, and liver function among HCV genotype 1a patients. Gastroenterol Hepatol from Bed to Bench. 2018;2019(12):S156–62.
Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol. 2017;206(2):165–74.
pubmed: 28214926
doi: 10.1007/s00430-017-0497-y
Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-Cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911–27.
pubmed: 12663797
pmcid: 152117
doi: 10.1128/JVI.77.8.4911-4927.2003
Kalantar K, Khansalar S, Eshkevar Vakili M, Ghasemi D, Dabbaghmanesh MH, Amirghofran Z. Association of Foxp3 gene variants with risk of Hashimoto’s thyroiditis and correlation with anti-tpo antibody levels. Acta Endocrinol (Copenh). 2019;15(4):423–9.
An I, Harman M, Ibiloglu I. Topical ciclopiroxoOlamine 1%: revisiting a unique antifungal. Indian Dermatol Online J. 2017;10(4):481–5.
Song P, Wang XW, Li HX, Li K, Liu L, Wei C, et al. Association between FOXP3 polymorphisms and vitiligo in a Han Chinese population. Br J Dermatol. 2013;169(3):571–8. https://doi.org/10.1111/bjd.12377 .
doi: 10.1111/bjd.12377
pubmed: 23582052
Claassen MAA, De KRJ, Tilanus HW, Janssen HLA, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis q. J Hepatol. 2010;52(3):315–21. https://doi.org/10.1016/j.jhep.2009.12.013 .
doi: 10.1016/j.jhep.2009.12.013
pubmed: 20129690
Ward SM, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol. 2007;47(3):316–24.
pubmed: 17475362
doi: 10.1016/j.jhep.2007.03.023
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21.
pubmed: 24428467
doi: 10.1056/NEJMoa1306218
Pereira LMS, Gomes STM, Ishak R, Vallinoto ACR. Regulatory T cell and forkhead box protein 3 as modulators of immune homeostasis. Front Immunol. 2017;8:1–24.
doi: 10.3389/fimmu.2017.00605
Beiranvand E, Abediankenari S, Khani S, Hosseini HM, Zeinali S, Beiranvand B, et al. G allele at -924 A > G position of FoxP3 gene promoter as a risk factor for tuberculosis. BMC Infect Dis. 2017;17(1):4–9.
doi: 10.1186/s12879-017-2762-5
Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, et al. Comparative ability of IL-12 and IL-28B to regulate treg populations and enhance adaptive cellular immunity. Blood, J Am Soc Hematol. 2009;113(23):5868–77.
Cd CD, Regulatory F, In TC, Chen X, Zhu B, Luo ÞY, et al. Interleukin-28B plays a therapeutic role on mouse U14 cervical cancer cells by down-regulating. Int J Gynecol Cancer. 2015;25(8):1369–76.
doi: 10.1097/IGC.0000000000000528